CoChat
Sign Up
Cited by 470Growth Hormone and Insulin-like Growth FactorsDiabetes, Cardiovascular Risks, and LipoproteinsBirth, Development, and Health

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study

Sandhu, Manjinder S, Heald, Adrian H, Gibson, J Martin, Cruickshank, J Kennedy, Dunger, David B, Wareham, Nicholas J·2002·The Lancet
DOI 10.1016/s0140-6736(02)08655-5
Open this paper in CoChat — free account

Abstract

Background Results of experimental and clinical studies suggest that insulin-like growth factor-I (IGF-I) and IGF binding protein-1 (IGFBP-1) could be important determinants of glucose homoeostasis. However, experimental models might also reflect compensatory and adaptive metabolic processes. We therefore prospectively examined the associations between circulating concentrations of IGF-I and IGFBP-1 and development of glucose tolerance.Methods Participants in this cohort study were a random sample of 615 normoglycaemic men and women aged 45-65 years. Participants underwent oral glucose tolerance testing based on WHO definitions and criteria in 1990-92 and 1994-96. At the baseline visit, we measured serum concentrations of IGF-I and IGFBP-1, and assessed the relation between these peptides and subsequent glucose intolerance.Findings At 4.5 years of follow-up, 51 (8%) of 615 participants developed impaired glucose tolerance or type-2 diabetes. After adjustment for correlates of IGF-I and risk factors for glucose intolerance, the odds ratio for risk of impaired glucose tolerance or type-2 diabetes for participants with IGF-I concentrations above the median (> or = 152 microg/L) compared with those with concentrations below the median (<152 microg/L) was 0.50 (0.26-0.95). Consistent with this finding, IGF-I also showed a significant inverse association with subsequent 2-h glucose concentrations, which was independent of correlates of IGF-I and risk factors for glucose tolerance (p for linear trend=0.026). We also found that this inverse association was independently modified by IGFBP-1 (p for interaction=0.011).Interpretation These data show that circulating IGF-I and its interaction with IGFBP-1 could be important determinants of glucose homoeostasis and provide further evidence for the possible protective role of IGF-I against development of glucose intolerance.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(02)08655-5

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. 1996, Evidence from a dose ranging study that recombinant insulin-like growth factor-I effectively and safely improves glycaemic control in non-insulin dependent diabetes mellitus, Diabetes, 45, 27A
  2. Vaessen N. Population-based evidence for genetically programmed failure of the beta-cell in type 2 diabetes. In: Genetic determinants of diabetes and vascular complications, PhD thesis, Rotterdam, the Netherlands, 2001.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sandhu, M. S., Heald, A. H., Gibson, J. M., Cruickshank, J. K., Dunger, D. B., & Wareham, N. J.
Affiliations
  • University of Cambridge (GB)
  • University of Manchester (GB)
Corresponding author
Wareham, Nicholas J
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2002-05
Volume
359
Issue
9319
Pages
1740-1745
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(02)08655-5
OpenAlex
W2140997600
Cited by
470
References
33
Citations by year
2026: 3 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 18 · 2017: 18 · 2016: 17 · 2015: 14 · 2014: 19 · 2013: 11 · 2012: 28
FWCI
15.22
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
Keywords
insulin-like growth factor I, IGF-binding protein-1, impaired glucose tolerance, type 2 diabetes, glucose homeostasis, 2-hour plasma glucose, middle-aged adults
MeSH terms
Aged, Blood Glucose, Fasting, Female, Homeostasis, Humans, Insulin-Like Growth Factor I, Male, Middle Aged, Prospective Studies, Glucose Intolerance, Insulin-Like Growth Factor Binding Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review